Search results for " dose"

showing 10 items of 593 documents

Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ ind…

2021

Once-daily (o.d.) fixed-dose combinations of mometasone furoate/indacaterol acetate (MF/IND) and mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY), both delivered via the Breezhaler® device, are approved for the maintenance treatment of asthma. Across these fixed-dose combinations, while the doses of bronchodilators remain the same, the nominal doses of mometasone furoate in micrograms differ. This article presents the steps followed in bridging the mometasone furoate doses at the corresponding dose strengths in the mometasone furoate formulation delivered via the Twisthaler® and mometasone furoate/indacaterol acetate and mometasone furoate/indacaterol acetate/glyco…

Pulmonary and Respiratory Medicinemedicine.drug_classMometasone furoateQuinolonesPharmacologyFixed doseAdministration InhalationHumansMedicinePharmacology (medical)In patientGlycopyrronium bromideAsthmabusiness.industryBiochemistry (medical)medicine.diseaseGlycopyrrolateAsthmaBronchodilator AgentsDrug CombinationsTreatment OutcomeIndansIndacaterolCorticosteroidOnce dailybusinessMometasone Furoatemedicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?

2015

Inhalation is the preferred route of drug administration in chronic respiratory diseases because it optimises delivery of the active compounds to the targeted site and minimises side effects from systemic distribution. The choice of a device should be made after careful evaluation of the patient's clinical condition (degree of airway obstruction, comorbidities), as well as their ability to coordinate the inhalation manoeuvre and to generate sufficient inspiratory flow. These patient factors must be aligned with the specific advantages and limitations of each inhaler when making this important choice. Finally, adherence to treatment is not the responsibility of the patient alone, but should …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveSocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioAffect (psychology)Anti-asthmatic AgentMedication AdherencePulmonary DiseasePulmonary Disease Chronic ObstructiveSuspensionsAdministration InhalationmedicineCOPDHumansPharmacology (medical)Anti-Asthmatic AgentsMetered Dose InhalersRespiratory systemParticle SizeIntensive care medicineAsthmaAdherence; Asthma; COPD; Inhaler; Administration Inhalation; Anti-Asthmatic Agents; Dry Powder Inhalers; Humans; Medication Adherence; Metered Dose Inhalers; Particle Size; Pulmonary Disease Chronic Obstructive; Solutions; Suspensions; Nebulizers and Vaporizers; Pulmonary and Respiratory Medicine; Pharmacology (medical); Biochemistry (medical); Medicine (all)COPDInhalationbusiness.industryMedicine (all)InhalerNebulizers and VaporizersBiochemistry (medical)Adherence; Asthma; COPD; Inhaler; Administration Inhalation; Anti-Asthmatic Agents; Dry Powder Inhalers; Humans; Medication Adherence; Metered Dose Inhalers; Particle Size; Pulmonary Disease Chronic Obstructive; Solutions; Suspensions; Nebulizers and Vaporizers; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)InhalerDry Powder InhalersAirway obstructionmedicine.diseaseAsthmaSolutionsInhalationAdherenceAdministrationAdherence; Asthma; COPD; InhalerbusinessPulmonary pharmacologytherapeutics
researchProduct

What drives inhaler prescription for asthma patients? Results from a real-life retrospective analysis

2020

Abstract Background The choice of inhaler device for asthma patients depends upon multiple attributes. We investigated factors that may drive general practitioners (GPs) and respiratory specialists in the prescription of inhaler devices for asthma patients who initiated inhalation therapy. Methods We retrospectively analysed prescriptions by GPs and respiratory specialists to asthma patients commencing inhaled corticosteroid/long-acting β2-agonist combination therapy available as both pressurised metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs). Patient characteristics were compared by device and multivariate analysis was used to model the likelihood of receiving a pMDI as oppos…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyMultivariate analysisSettore MED/10 - Malattie Dell'Apparato RespiratorioGeneral practitioner03 medical and health sciencesdry powder inhaler0302 clinical medicineInhalersAdrenal Cortex HormonesAdrenergic beta-2 Receptor AntagonistsAsthma controlGeneral practitionersAdministration InhalationRetrospective analysisMedicine030212 general & internal medicineMetered Dose InhalersMedical prescriptionAsthmaRetrospective Studiesbusiness.industryInhalerdry powder inhalersInhalerOdds ratiomedicine.diseaseConfidence intervalAsthmaPressurised metered-dose inhalerAsthma; dry powder inhalers; General practitioners; Inhalers; Pressurised metered-dose inhalers; Respiratory specialistsPrescriptions030228 respiratory systemRespiratory specialistsInhalationDelayed-Action PreparationsEmergency medicineAdministrationPressurised metered-dose inhalersbusinessAsthma; dry powder inhalers; General practitioners; Inhalers; Pressurised metered-dose inhalers; Respiratory specialists; Administration Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Antagonists; Asthma; Delayed-Action Preparations; Retrospective Studies; Dry Powder Inhalers; Metered Dose Inhalers; Prescriptions
researchProduct

Eligibility for treatment with omalizumab in Italy and Germany.

2013

Summary Omalizumab is an add-on therapy for patients with uncontrolled severe allergic asthma. In Europe, patients must fulfil a number of additional criteria to become eligible for omalizumab therapy, creating a challenge for epidemiology studies to quantify the potential patient pool. Thus, and in the absence of robust data, the number of omalizumab-eligible patients has remained unclear. To assess eligible patient numbers, a chart-audit design approach was employed to measure epidemiology variables based on patient-level data. 770 patient charts were reviewed in designated towns in Germany and Italy, in collaboration with >200 primary care physicians (PCPs) and respiratory specialists (R…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPediatricsReferralEpidemiologySevere asthmaAllergic asthmaEligibility DeterminationOmalizumabPrimary careOmalizumabAntibodies Monoclonal HumanizedSeverity of Illness IndexAntibodiesSampling StudiesDose-Response RelationshipProduct LabelGermanyEpidemiologyMonoclonalmedicinePrevalenceHumansNational levelAnti-Asthmatic AgentsHumanizedAnti-immunoglobulin EEligibilityDose-Response Relationship Drugbusiness.industryPatient SelectionAllergic asthmaImmunoglobulin EAsthmaAntibodies Anti-IdiotypicAnti-IdiotypicTreatment OutcomeItalyQuality of LifeBiological MarkersDrugbusinessBiomarkersmedicine.drugAllergic asthma; Anti-immunoglobulin E; Eligibility; Epidemiology; Anti-Asthmatic Agents; Antibodies Anti-Idiotypic; Antibodies Monoclonal Humanized; Asthma; Biological Markers; Dose-Response Relationship Drug; Eligibility Determination; Germany; Humans; Immunoglobulin E; Italy; Patient Selection; Prevalence; Quality of Life; Sampling Studies; Severity of Illness Index; Treatment OutcomeRespiratory medicine
researchProduct

Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma

2021

INTRODUCTION Asthma symptoms can be relieved through a maintenance treatment combining long-acting β2-agonist and inhaled corticosteroids (LABA/ICS). However, for patients with inadequately controlled asthma, the LABA/ICS combination might not be sufficient. Under these conditions, clinical guidelines recommend the administration of inhaled long-acting muscarinic antagonists (LAMA) as an add-on therapy to LABA/ICS to better control asthma and improve lung function. For nearly two decades, the only LAMA to be approved on the market has been tiotropium. AREAS COVERED We reviewed recent clinical studies evaluating the safety and efficacy of LABA/LAMA/ICS fixed dose combinations by searching Pu…

Pulmonary and Respiratory Medicinemedicine.medical_specialtycorticosteroidFixed-dose combinationLABAAsthma corticosteroid fixed dose combination ICS inhaler LABA LAMA once daily combination uncontrolled asthmaMuscarinic Antagonistsonce daily combinationQuinolonesSettore MED/10 - Malattie Dell'Apparato RespiratorioinhalerAdrenal Cortex HormonesInternal medicineAdministration InhalationImmunology and AllergyMedicineHumansfixed dose combinationAdrenergic beta-2 Receptor AgonistsAsthmaFluticasonebiologyInhalationuncontrolled asthmabusiness.industryInhalerPublic Health Environmental and Occupational HealthLAMALamamedicine.diseasebiology.organism_classificationGlycopyrrolateFluticasone-Salmeterol Drug CombinationAsthmarespiratory tract diseasesDrug CombinationsICSIndansIndacaterolSalmeterolbusinessMometasone Furoatehormones hormone substitutes and hormone antagonistsmedicine.drug
researchProduct

Changes in radiological protection and quality control in Spanish dental installations: 1996-2003.

2008

Introduction: The European Union has established specific directives concerning radiological protection which are obligatory for member States. In addition, all Spanish dental clinics with radiological equipment are required to have an annual quality control check. Objective: To analyze the effect of new European legislation on dental radiological practice in Spain and to determine whether it has resulted in lower doses being administered to patients. Material and Methods: A total of 10,171 official radiological quality control reports on Spanish dental clinics, covering 16 autonomous regions, were studied following the passing of Royal Decree 2071/1995 on quality criteria in radiodiagnosti…

Quality ControlPathologymedicine.medical_specialtymedia_common.quotation_subjectRadiation Protectionmedicinemedia_common.cataloged_instanceHumansQuality (business)European unionGeneral Dentistrymedia_commonRoyal decreebusiness.industryMember statesDental Clinics:CIENCIAS MÉDICAS [UNESCO]Skin dosemedicine.diseaseOtorhinolaryngologySpainRadiological weaponUNESCO::CIENCIAS MÉDICASSurgeryMedical emergencybusinessMedicina oral, patologia oral y cirugia bucal
researchProduct

Discrimination of Radiation Quality Through Second Harmonic Out-of-Phase cw-ESR Detection

2014

The ability to discriminate the quality of ionizing radiation is important because the biological effects produced in tissue strongly depends on both absorbed dose and linear energy transfer (LET) of ionizing particles. Here we present an experimental electron spin resonance (ESR) analysis aimed at discriminating the effective LETs of various radiation beams (e.g., 19.3 MeV protons, 60Co photons and thermal neutrons). The measurement of the intensities of the continuous wave spectrometer signal channel first harmonic in-phase and the second harmonic out-of-phase components are used to distinguish the radiation quality. A computational analysis, was carried out to evaluate the dependence of …

Quality ControlTime FactorsPhotonTime FactorBiophysicsLinear energy transferRadiationIonizing radiationQuality (physics)OpticsRadiation IonizingLinear Energy TransferRadiology Nuclear Medicine and imagingMicrowavesRadiationChemistrybusiness.industryElectron Spin Resonance SpectroscopySettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)EPR spectroscopy; radiation effectsBiophysicAbsorbed doseradiation effectsHarmonicContinuous waveAtomic physicsbusinessMicrowaveEPR spectroscopyRadiation Research
researchProduct

Use of molecular topology for the prediction of physico-chemical, pharmacokinetic and toxicological properties of a group of antihistaminic drugs

2002

We used molecular connectivity to search mathematical models for predicting physico-chemical (e.g. the partition coefficient, P), pharmacokinetic (e.g. the time of maximum plasma level, and toxicological properties (lethal dose, LD) for a group of antihistaminic drugs. The results obtained clearly reveal the high efficiency of molecular topology for the prediction of these properties. Randomization and cross-validation by use of leave-one-out tests were also performed in order to assess the stability and the prediction ability of the connectivity functions selected.

Quantitative structure–activity relationshipChemistryQuantitative Structure-Activity RelationshipPharmaceutical SciencePlasma levelsPharmacologyModels BiologicalLethal Dose 50Structure-Activity RelationshipPharmacokineticsPredictive Value of TestsHistamine H1 AntagonistsRegression AnalysisAntihistaminic drugsMolecular topologyBiological systemInternational Journal of Pharmaceutics
researchProduct

Aza-isoindolo and isoindolo-azaquinoxaline derivatives with antiproliferative activity

2015

Abstract Three new ring systems, pyrido[2′,3′:3,4]pyrrolo[1,2- a ]quinoxalines, pyrido[3′,2′:3,4]pyrrolo[1,2- a ]quinoxalines and pyrido[2′,3′:5,6]pyrazino[2,1- a ]isoindoles, were synthesized through an aza-substitution on the already active isoindolo-quinoxaline system and in particular in the position 7 or 4 of the isoindole moiety and in position 5 of the quinoxaline portion. All new compounds were screened by the National Cancer Institute (Bethesda, MD) against a panel of 60 human tumor cell lines. Biological results of the most active derivatives, with pGI 50 values between 7.09 and 7.27, confirmed the importance of the presence of methoxy substituents for biological activity. The ant…

QuinoxalineIsoindolesAzaisoindolo-quinoxalinesStereochemistryAntiproliferative activity; Apoptosis; Azaisoindolo-quinoxalines; DNA interaction; Isoindolo-azaquinoxalines; Quinoxalines; Antineoplastic Agents; Apoptosis; Aza Compounds; Cell Line Tumor; Cell Proliferation; Dose-Response Relationship Drug; Drug Screening Assays Antitumor; Humans; Isoindoles; Molecular Structure; Quinoxalines; Structure-Activity Relationship; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry; Pharmacology; Medicine (all)ApoptosisAntineoplastic AgentsAntiproliferative activityIsoindolesRing (chemistry)Drug Screening AssaysCell LineDose-Response Relationshipchemistry.chemical_compoundStructure-Activity RelationshipQuinoxalineCell Line TumorQuinoxalinesDrug DiscoverymedicineMoietyHumansAntiproliferative activity; Apoptosis; Azaisoindolo-quinoxalines; DNA interaction; Isoindolo-azaquinoxalines; Quinoxalines; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry; PharmacologyCell ProliferationPharmacologyAza CompoundsAzaisoindolo-quinoxalineTumorDose-Response Relationship DrugMolecular StructureDrug Discovery3003 Pharmaceutical ScienceMedicine (all)Organic ChemistryApoptosiBiological activityGeneral MedicineAntitumorCell cycleSettore CHIM/08 - Chimica FarmaceuticaDNA interactionSettore ING-IND/22 - Scienza E Tecnologia Dei MaterialiMechanism of actionchemistryIsoindolo-azaquinoxalineDrug Screening Assays Antitumormedicine.symptomDrugIsoindoleIsoindolo-azaquinoxalines
researchProduct

Efficacy of raw implementation and reduction dose protocols in CT colonoscopy: a single centre 4 years retrospective review

2015

Aims and objectives Methods and materials Results Conclusion Personal information References

Radiation safetyRadioprotection / Radiation dose CT Radiation safety Dosimetric comparisongenetic structuresRadioprotection / Radiation doseDosimetric comparisonCT
researchProduct